title: Inhibition of glutamate release by delaying ATP fall accounts for neuroprotective effects of antioxidants in experimental stroke.
abstract: Excitotoxic neuronal injury related to excessive glutamate release is believed to play a key role in the pathogenesis of focal cerebral ischemia. Reversal of neuronal glutamate transporters caused by ATP fall and subsequent imbalance of membrane ionic gradients accounts for most glutamate release after cerebral ischemia. ATP synthesis from oxidative phosphorylation derives from the coupled functioning of the mitochondrial respiratory chain (MRC) and the ATP synthase; interestingly, the MRC is one of the main sites of cellular reactive oxygen species (ROS) generation even in physiological circumstances. Hence, we have studied the effect of the antioxidants glutathione, superoxide dismutase, and alpha-tocopherol on infarct outcome, brain ATP, and glutamate levels after permanent middle cerebral artery occlusion (MCAO) in Fischer rats; we have also characterized the actions of antioxidants on MRC complexes. Our results show that intraperitoneal administration of antioxidants 2 h before MCAO enhances ATP synthesis and causes a neuroprotective effect concomitant to inhibition of ischemia-induced increase in brain glutamate. Antioxidants also increased mitochondrial ATP and MRC complex I-III activity and respiration, suggesting that these actions are due to removal of the inhibition caused by endogenous ROS on MRC. These findings may possess important therapeutic repercussions in the management of ischemic stroke.
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D019069:Cell Respiration / Q000187:drug effects; D004579:Electron Transport / Q000187:drug effects; D018698:Glutamic Acid / Q000378:metabolism*; D005978:Glutathione / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000150:complications; D007700:Kinetics; D008297:Male; D008665:Metalloporphyrins / Q000627:therapeutic use; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018384:Oxidative Stress; D051381:Rats; D011916:Rats, Inbred F344; D017382:Reactive Oxygen Species / Q000378:metabolism; D020521:Stroke / Q000378:metabolism / Q000517:prevention & control*; D024505:Tocopherols / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D008665:Metalloporphyrins; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; C097284:manganese(III)-tetrakis(4-benzoic acid)porphyrin; D018698:Glutamic Acid; D000255:Adenosine Triphosphate; D005978:Glutathione; D024505:Tocopherols